Heartland Advisors Inc. Has $13.95 Million Stock Position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY)

Key Points

• Heartland Advisors Inc. has increased its stake in DENTSPLY SIRONA by 31.1%, now owning 933,850 shares valued at approximately $13.95 million.
• DENTSPLY SIRONA reported earnings per share of $0.43 for the last quarter, surpassing analysts' expectations, but revenue fell 7.8% year-over-year.
• The company recently declared a quarterly dividend of $0.16, representing an annualized yield of 3.89%, though its dividend payout ratio is currently -14.10%.

Heartland Advisors Inc. raised its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) by 31.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 933,850 shares of the medical instruments supplier's stock after purchasing an additional 221,450 shares during the period. Heartland Advisors Inc. owned 0.47% of DENTSPLY SIRONA worth $13,952,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of DENTSPLY SIRONA during the first quarter valued at about $287,000. Y Intercept Hong Kong Ltd lifted its position in DENTSPLY SIRONA by 128.3% during the first quarter. Y Intercept Hong Kong Ltd now owns 49,926 shares of the medical instruments supplier's stock valued at $746,000 after purchasing an additional 28,053 shares during the last quarter. Allianz Asset Management GmbH lifted its holdings in shares of DENTSPLY SIRONA by 57.4% in the 1st quarter. Allianz Asset Management GmbH now owns 530,257 shares of the medical instruments supplier's stock worth $7,922,000 after acquiring an additional 193,409 shares during the last quarter. CWM LLC lifted its holdings in DENTSPLY SIRONA by 124.5% during the 1st quarter. CWM LLC now owns 95,087 shares of the medical instruments supplier's stock valued at $1,421,000 after buying an additional 52,727 shares in the last quarter. Finally, Ballentine Partners LLC purchased a new position in DENTSPLY SIRONA during the 1st quarter valued at about $210,000. 95.70% of the stock is owned by institutional investors.

DENTSPLY SIRONA Price Performance

NASDAQ XRAY opened at $16.46 on Friday. DENTSPLY SIRONA Inc. has a 52-week low of $12.16 and a 52-week high of $27.95. The firm's 50 day moving average price is $16.05 and its 200-day moving average price is $16.22. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.76 and a current ratio of 1.10. The company has a market cap of $3.28 billion, a PE ratio of -3.63, a P/E/G ratio of 1.20 and a beta of 0.94.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical instruments supplier reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.14. The firm had revenue of $879.00 million for the quarter, compared to the consensus estimate of $854.75 million. DENTSPLY SIRONA had a negative net margin of 24.42% and a positive return on equity of 14.31%. The firm's revenue for the quarter was down 7.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.42 EPS. Sell-side analysts forecast that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current fiscal year.

DENTSPLY SIRONA Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, July 11th. Stockholders of record on Friday, June 27th were given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 3.89%. The ex-dividend date of this dividend was Friday, June 27th. DENTSPLY SIRONA's dividend payout ratio (DPR) is -14.10%.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Barrington Research reissued an "outperform" rating and set a $21.00 target price on shares of DENTSPLY SIRONA in a research report on Tuesday. Morgan Stanley lowered shares of DENTSPLY SIRONA from an "overweight" rating to an "equal weight" rating and set a $14.00 price objective for the company. in a report on Tuesday, April 15th. Wall Street Zen raised shares of DENTSPLY SIRONA from a "hold" rating to a "buy" rating in a research report on Sunday, July 13th. Piper Sandler lowered their target price on shares of DENTSPLY SIRONA from $20.00 to $16.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 30th. Finally, UBS Group cut their target price on shares of DENTSPLY SIRONA from $27.00 to $25.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Ten investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $19.60.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.